The catastrophic antiphospholipid (Asherson's) syndrome in 2004 - a review

被引:44
作者
Asherson, RA [1 ]
机构
[1] Univ Cape Town, Ctr Hlth Sci, Rheumat Dis Unit, ZA-7925 Cape Town, South Africa
[2] Groote Schuur Hosp, ZA-7925 Cape Town, South Africa
[3] Rosebank Clin, Johannesburg, South Africa
关键词
multiorgan thrombosis; antiphospholipid antibodies; Catastrophic (Asherson's) Syndrome; plasmapheresis; IVGammaglobulins;
D O I
10.1016/j.autrev.2004.03.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
An unusual variant of the antiphospholipid syndrome (APS) termed the Catastrophic Antiphospholipid Syndrome (CAPS) in 1992 by Asherson is described. The condition may arise "de-novo" in a patient previously not suspected of having an APS or during the course of a "Primary" APS or Secondary APS (most commonly SLE). The patient may already be on therapy. "Trigger" factors (infections most commonly) have been identified in 45% of patients but in the majority, they remain unidentified. Clinically, the patients present with small vessel occlusions involving organs (e.g. bowel, brain, heart, kidney) but large vessels occlusions do occur. Unusual organs are involved and the clinical features depend on which organs are affected. Because of tissue necrosis, the Systemic Inflammatory Response ensues ("SIRS") and many patients develop ARDS. Despite seemingly adequate therapy (parenteral heparin, steroids, antibiotics), the mortality remains high (approximately 50%). (C) 2004 Published by Elsevier B.V.
引用
收藏
页码:48 / 54
页数:7
相关论文
共 29 条
  • [11] ANCROD IN SYSTEMIC LUPUS-ERYTHEMATOSUS WITH THROMBOSIS - CLINICAL AND FIBRINOLYSIS EFFECTS
    DOSEKUN, AK
    POLLAK, VE
    GLASGREENWALT, P
    KANT, KS
    PENOVICH, P
    LEBRONBERGES, A
    WEISS, MA
    LEVINSON, JE
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1984, 144 (01) : 37 - 42
  • [12] EHRESMANN S, 2004, 7 INT C SLE REL COND, P330
  • [13] Catastrophic antiphospholipid syndrome - Where do we stand?
    Erkan, D
    Cervera, R
    Asherson, RA
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (12): : 3320 - 3327
  • [14] Long term outcome of catastrophic antiphospholipid syndrome survivors
    Erkan, D
    Asherson, RA
    Espinosa, G
    Cervera, R
    Font, J
    Piette, JC
    Lockshin, MD
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (06) : 530 - 533
  • [15] ERKAN D, 2004, IN PRESS LUPUS
  • [16] Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies
    Espinosa, G
    Bucciarelli, S
    Cervera, R
    Lozano, M
    Reverter, JC
    de la Red, G
    Gil, V
    Ingelmo, M
    Font, J
    Asherson, RA
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (06) : 730 - 736
  • [17] Flamholz R, 1999, J CLIN APHERESIS, V14, P171, DOI 10.1002/(SICI)1098-1101(1999)14:4<171::AID-JCA3>3.0.CO
  • [18] 2-5
  • [19] New developments in viral peptides and APL induction
    Gharavi, AE
    Pierangeli, SS
    Harris, EN
    [J]. JOURNAL OF AUTOIMMUNITY, 2000, 15 (02) : 227 - 230
  • [20] Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides
    Gharavi, EE
    Chaimovich, H
    Cucurull, E
    Celli, CM
    Tang, H
    Wilson, WA
    Gharavi, AE
    [J]. LUPUS, 1999, 8 (06) : 449 - 455